In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines
Entity
UAM. Departamento de Bioquímica; Centro de Biología Molecular Severo Ochoa (CBM)Publisher
Oxford University PressDate
2017-12-19Citation
10.1093/carcin/bgx146
Carcinogenesis 39.3 (2018): 447-457
ISSN
0143-3334 (print); 1460-2180 (online)DOI
10.1093/carcin/bgx146Funded by
BIO-0139, CTS-1406, PI-639-2012, PI-0541-2013 (Junta de Andalucia), BFU2013-43282-R, BFU2016-80360-R (MINECO), PI13-00651, PI16/00264 (Proyectos de Investigación en Salud FIS, funded by Instituto de Salud Carlos III), GETNE Grant 2014, Merck Serono Grant 2013 and CIBERobn (to RML and JPC); PI13/00132, RETICC RD12/0036/0007, CIBERonc and S2010/BMD-2303 (to GMB)Project
Gobierno de España. BFU2013-43282-R; Gobierno de España. BFU2016-80360-R; Gobierno de España. PI13-00651; Gobierno de España. PI16/00264; Comunidad de Madrid. S2010/BMD-2303/RECAREEditor's Version
http://doi.org/10.1093/carcin/bgx146Subjects
In1-ghrelin; Splicing variant; Breast cancer; Malignancy; Survival; MedicinaNote
OXFORD UNIVERSITY: This is a pre-copyedited, author-produced version of an article accepted for publication in Carcinogenesis following peer review. The version of record David Rincón-Fernández, Michael D Culler, Natia Tsomaia, Gema Moreno-Bueno, Raúl M Luque, Manuel D Gahete, Justo P Castaño; In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines, Carcinogenesis, Volume 39, Issue 3, 8 March 2018, Pages 447–457, https://doi.org/10.1093/carcin/bgx146Rights
© The Author(s) 2018. Published by Oxford University Press. All rights reservedAbstract
Ghrelin gene generates several variants that regulate multiple pathophysiological functions, including tumor-related processes. In1-ghrelin is a splicing variant that was previously shown to be overexpressed in breast cancer (BCa), where it correlated with proliferation markers; however, its possible association with clinical outcome of BCa patients and underlying mechanisms are still unknown. To address this issue, expression levels and clinical associations of In1-ghrelin were analyzed in a cohort of 117 BCa samples. Additionally, a battery of cellular and molecular assays was implemented using two BCa cell lines (MCF-7 and MDA-MB-231), wherein the role of In1-ghrelin on proliferation, migration, dedifferentiation and signaling pathways was explored. The results generated revealed that high expression of In1-ghrelin in BCa samples was associated with lymph node metastasis and reduced disease-free survival. Indeed, In1-ghrelin overexpression stimulated proliferation and migration in MCF-7 and MDA-MB-231 cells. Similar results were found by treating MDA-MB-231 and MCF-7 with In1- ghrelin-derived peptides. Conversely, In1-ghrelin silencing decreased proliferation and migration capacities of MDA-MB-231. Furthermore, In1-ghrelin (but not ghrelin) overexpression increased the capacity to form mammospheres in both cell lines. These effects could be associated with activation of MAPK-ERK, Jag1/Notch, Wnt/β-catenin and/or TGF-β1 pathways. Altogether, our data indicate that In1-ghrelin could play relevant functional roles in the regulation of BCa development and progression and may provide insights to identify novel biomarkers and new therapeutic approaches for this pathology.
Files in this item
Google Scholar:Rincón-Fernández, David
-
Culler, Michael D.
-
Tsomaia, Natia
-
Moreno Bueno, Gema
-
Luque, Raúl M.
-
Gahete, Manuel D.
-
Castaño, Justo P.
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.